Morgan Stanley
ZYBT

Morgan Stanley’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Morgan Stanley’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168 Sell
248
-13
-5% -$12 ﹤0.01% 7876
2026
Q1 		$244 Sell
261
-1,346
-84% -$1.26K ﹤0.01% 7682
2025
Q4 		$1.85K Sell
1,607
-402
-20% -$891 ﹤0.01% 7258
2025
Q3 		$5.26K Sell
2,009
-427
-18% -$2.96K ﹤0.01% 7073
2025
Q2 		$14.5K Buy
2,436
+2,390
+5,196% +$19K ﹤0.01% 6751
2025
Q1 		$247 Buy
+46
New +$214 ﹤0.01% 7452

Other funds holding ZYBT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's ZYBT Position: Q2 2026 in Review

Morgan Stanley reduced its Zhengye Biotechnology Holding (ZYBT) stake by 5% in Q2 2026, selling an estimated $12 and leaving 248 shares worth $168. The position accounts for ﹤0.01% of the portfolio, ranked #7876.

Morgan Stanley first reported a position in ZYBT in Q1 2025 and has held it in 6 quarters since. The position peaked at $14.5K in Q2 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

  • Morgan Stanley held 248 shares of Zhengye Biotechnology Holding worth $168 as of Q2 2026.
  • Morgan Stanley sold 13 Zhengye Biotechnology Holding shares in Q2 2026, an estimated $12.
  • Zhengye Biotechnology Holding made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7876 holding.
  • Morgan Stanley first reported a position in Zhengye Biotechnology Holding in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Zhengye Biotechnology Holding position peaked at $14.5K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.